manjaro glp 1 agonist Mounjaro (tirzepatide) for the Treatment of Type 2 Diabetes, USA Mounjaro (tirzepatide) GLP-1 prescription online

Ethics declarations Ethical approval and consent to participate Not applicable

A product is included if it is an FDA or EMA-approved prescription GLP-1 receptor agonist therapy indicated for type 2 diabetes, obesity, or cardiovascular risk reduction

Clinical evidence, although still emerging, aligns with these findings

The demand for tirzepatide has outpaced supply since its launch, and the search for effective alternatives has become one of the most common questions in weight management and metabolic health research

According to a 2024 poll, one in eight adults has at least tried this medication class

Abstract Purpose of Review Obesity pharmacotherapy is rapidly evolving with the ability of glucagon-like peptide- 1 receptor agonists (GLP-1RAs) to improve atherosclerotic cardiovascular disease (ASCVD) outcomes